AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03319017 — intervention group
Intervention type: PROCEDURE
Intervention: Multiple-trauma patients
Description: The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.~A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed.
Study NCT00880906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal dilation
Description: The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
Study NCT00880906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid and Proton Pump Inhibitor Therapy
Study NCT00880906 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Steroid and Proton Pump Inhibitor Therapy
Study NCT02355535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-1
Description: PAC-1 is taken orally on days 1-21 of a 28-day cycle.
Study NCT04247204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma intrauterine infusion
Description: For all women, basic transvaginal sonography will be done in the 2nd day of frozen embryo transfer (FET) cycle and they will receive standard hormone replacement therapy (HRT) in the form of estradiol valerate tablets (white tablets of Cyclo-Progynova; Bayer Schering Pharma AG, Germany) at a dose of 4mg for 7 days then 6mg for 6 days. Endometrial assessment will be done on day 15 of FET cycle. Those with endometrial thickness between 8-14 mm will be evaluated for endometrial and sub-endometrial vasculature pattern by 3D power Doppler analysis. Then 1 ml of PRP (prepared from autologous blood) will be infused in the uterine cavity and vaginal progesterone 400 mg twice daily will be prescribed for 3 days. Subsequently, D3 embryos will be transferred. Endometrial, sub-endometrial and uterine arterial vascularity pattern will be re-evaluated on the day of ET. Both estradiol valerate tablets and vaginal progesterone will be continued up to 12th week of gestation in case of pregnancy.
Study NCT01119950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 12.5 µg once daily
Description: NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study NCT01119950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 25.0 µg once daily
Description: NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study NCT01119950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 12.5 µg twice daily
Description: NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
Study NCT01119950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 50.0 µg once daily
Description: NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study NCT01119950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 25.0 µg twice daily
Description: NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
Study NCT01119950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 100.0 µg once daily
Description: NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study NCT01119950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237 50.0 µg twice daily
Description: NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
Study NCT01119950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to NVA237 once daily
Description: Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
Study NCT03269019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HIT with thrombosis
Description: Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
Study NCT01377623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Description: Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
Study NCT01377623 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
Study NCT02931851 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICU Families Website
Description: Professionally developed website for relatives of ICU patients
Study NCT02931851 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard Information provided online
Study NCT00434018 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wheelchair Skills Training
Description: Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
Study NCT00434018 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Basic Health Education
Description: Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
Study NCT00057850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00057850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Study NCT03895788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: niraparib
Description: Niraparib will be administered as a flat-fixed dose (100mg or 200 mg, daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
Study NCT03895788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib
Description: Brivanib will be administered as a flat-fixed dose (200mg, 400 mg, or 600 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area.
Study NCT01460342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg (2 x 2.5-mg tablets), given once daily as oral tablet
Study NCT01460342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
Study NCT01460342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
Study NCT02866214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session
Study NCT02866214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.~same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) .
Study NCT03498716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
Study NCT03498716 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered by IV, 600 mg/m\^2 every 2 weeks for 4 doses
Study NCT02107014 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Low Dose Naltrexone
Description: Naltrexone 4.5 mg p.o. nocte
Study NCT02276508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E. coli Nissle 1917
Description: Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
Study NCT01848548 — intervention group
Intervention type: PROCEDURE
Intervention: Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark
Description: The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
Study NCT02852863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum
Description: Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
Study NCT01591616 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lidocaine and prilocaine
Description: Appropriate dose of Oraqix based on weight will be given before tooth extraction
Study NCT03525119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection
Study NCT03525119 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: HAV Vaccine
Description: HAV Vaccine IM injection.
Study NCT04719169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluoroscopic enema
Description: Fluoroscopic enema
Study NCT02934048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7-day triple regimen guided by AST
Description: Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
Study NCT02934048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 10-day triple regimen guided by AST
Description: Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
Study NCT02934048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 14-day triple regimen guided by AST
Description: Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
Study NCT03516019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalized notices
Description: The personalized notices take into account if data were received over the previous week, and accordingly encourages the participant to use the device and send her data, or encourages the participant to continue using the device and sending data. A library of personalized notices with alternative motivational content was developed. Each time a notification is sent, it will be drawn at random from the library.
Study NCT00828412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram Skin Barrier Emulsion
Description: topical cream, twice daily, 6 weeks
Study NCT03516019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard notices
Description: The standard notices which are neutral and invite participants to wear the watch daily and to measure their blood pressure weekly.
Study NCT03525119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV Vaccine
Description: HAV Vaccine IM injection.
Study NCT03525119 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: TDV Placebo
Description: Placebo-matching (normal saline (0.9% NaCl) SC injection.
Study NCT03516019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: am notices
Description: notifications sent at 7 am.
Study NCT00828412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desonide Cream 0.05%
Description: topical cream, twice daily, 6 weeks
Study NCT03348137 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03525119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HAV Vaccine Placebo
Description: Placebo-matching (normal saline (0.9% NaCl) IM injection.
Study NCT03516019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pm notices
Description: notifications sent at 7 pm.
Study NCT03516019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: weekday notices
Description: notifications sent on Wednesday
Study NCT03743090 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography.
Description: A polysomnography will be performed for all of the patients the day before surgery (value of reference), and on the second postoperative day (in order to examine the influence of ECC on the development of OSA).
Study NCT03361124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Administration of additional 20 mU Oxytocin
Study NCT03361124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Administration of additional 20 mU Oxytocin
Study NCT04336189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Description: SP (Kamsidar) will be supplied by Kampala Pharmaceutical Industries (KPI), Uganda. SP will be given as a single dose consisting of 3 full strength tablets.
Study NCT04336189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine (DP)
Description: DP (Duo-Cotecxin) will be supplied by Holley-Cotec, Beijing, China. DP will consist of 3 full strength tablets given once a day for 3 consecutive days.
Study NCT03460158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane-L®
Description: Restylane-L® for the indication for mid-to-deep dermal implantation for moderate to severe facial wrinkles and folds, such as nasolabial folds.
Study NCT03460158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane-L® Lyft
Description: Restylane-L® Lyft is for the indication of implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds and malars (cheek/cheek bone area).
Study NCT03460158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restylane Silk®
Description: Restylane Silk® is for the indication for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
Study NCT01065116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL Blister-packs with Instruction leaflets
Description: AL Blister packs with instruction leaflets will be dispensed
Study NCT01065116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AL unit dose age specific pre-packs
Description: Age specific colour coded Unit dose pre-packs will be used
Study NCT02845882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine
Description: Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
Study NCT02688296 — intervention group
Intervention type: DEVICE
Intervention: Fibulock
Description: Fibulock intramedullary implant will be used to repair fibula fractures
Study NCT03124290 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: paced auditory serial addition test (PASAT)
Description: A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
Study NCT04373629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attentional modulation
Description: Attentional instructions when viewing faces will be given
Study NCT04373629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perceptual modulation
Description: Faces will be presented of varying durations
Study NCT04373629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: naturalistic viewing
Description: Faces will be viewed without specific instructions
Study NCT04071054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Carnation Ambulatory Monitor (CAM)
Description: 7-day detection of arrhythmias with Carnation Ambulatory Monitor (CAM)
Study NCT01913795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: integrated pest management
Description: integrated pest management and environmental strategy
Study NCT01913795 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: integrated pest management
Description: integrated pest management and environmental strategy
Study NCT01913795 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: air purifier
Description: air purifiers
Study NCT01913795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air purifier
Description: air purifiers
Study NCT01913795 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham air purifier
Description: sham air purifiers
Study NCT01339377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AO-1000
Description: Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
Study NCT02999451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: snare-assisted POEM
Description: POEM is performed by using a snare which is retracted into the sheath to expose the tip, leaving a 1-2mm length for operation.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a snare in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a snare.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a snare.~4. The mucosal incision is closed with endoclips.
Study NCT02999451 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: knife-assisted POEM
Description: POEM is performed by using a conventional endoscopic knife.~1. After submucosal injection, an initial 2-cm mucosal incision is made by a knife in the posterior esophageal wall.~2. A submucosal tunnel from the esophagus to the gastric cardia is created using a knife.~3. Full-thickness myotomy is performed and extended 2-3 cm beyond the esophagogastric junction (EGJ) using a knife.~4. The mucosal incision is closed with endoclips.
Study NCT04039048 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cerebellar transcranial direct current stimulation
Description: Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 20 minutes with a 2mA current.
Study NCT04039048 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cerebellar transcranial direct current stimulation
Description: Non-invasive brain stimulation technique is able to modulate the brain activity through a low-intensity current. The anodal will be positioned 1 cm below inion and cathodal in the right deltoid muscle. 30 seconds with a 2mA current.
Study NCT01507948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure
Description: PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
Study NCT04039048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Balance training will be performed through the Biodex Balance System for 20 minutes.
Study NCT04039048 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Balance training
Description: Balance training will be performed through the Biodex Balance System for 20 minutes.